Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Go back to Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC| Janex International, Inc. (NASDAQ: JANX) | Delayed: 14.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.34 | 52 Week High | $0.01 | |||
| Open | $14.34 | 52 Week Low | $0.00 | |||
| Day High | $14.34 | P/E | N/A | |||
| Day Low | $14.34 | EPS | $0.00 | |||
| Volume | 241 | |||||
